Dosanjh Davinder P S, Hinks Timothy S C, Innes John A, Deeks Jonathan J, Pasvol Geoffrey, Hackforth Sarah, Varia Hansa, Millington Kerry A, Gunatheesan Rubamalar, Guyot-Revol Valerie, Lalvani Ajit
Tuberculosis Immunology Group, Imperial College London, London, United Kingdom.
Ann Intern Med. 2008 Mar 4;148(5):325-36. doi: 10.7326/0003-4819-148-5-200803040-00003.
The role of new T-cell-based blood tests for tuberculosis in the diagnosis of active tuberculosis is unclear.
To compare the performance of 2 interferon-gamma assays and tuberculin skin testing in adults with suspected tuberculosis.
Prospective study conducted in routine practice.
2 urban hospitals in the United Kingdom.
389 adults, predominantly of South Asian and black ethnicity, with moderate to high clinical suspicion of active tuberculosis.
Tuberculin skin testing, the enzyme-linked immunospot assay (ELISpot) incorporating early secretory antigenic target-6 and culture filtrate protein-10 (standard ELISpot), and ELISpot incorporating a novel antigen, Rv3879c (ELISpot(PLUS)) were performed during diagnostic assessment by independent persons who were blinded to results of the other test.
Sensitivity, specificity, predictive values, and likelihood ratios.
194 patients had a final diagnosis of active tuberculosis, of which 79% were culture-confirmed. Sensitivity for culture confirmed and highly probable tuberculosis was 89% (95% CI, 84% to 93%) with ELISpot(PLUS), 85% (CI, 79% to 90%) with standard ELISpot, 79% (CI, 72% to 85%) with 15-mm threshold tuberculin skin testing, and 83% (CI, 77% to 89%) with stratified thresholds of 15 and 10 mm in vaccinated and unvaccinated patients, respectively. The ELISpot(PLUS) assay was more sensitive than tuberculin skin testing with 15-mm cutoff points (P = 0.01) but not with stratified cutoff points (P = 0.10). The ELISpot(PLUS) assay had 4% higher diagnostic sensitivity than standard ELISpot (P = 0.02). Combined sensitivity of ELISpot(PLUS) and tuberculin skin testing was 99% (CI, 95% to 100%), conferring a negative likelihood ratio of 0.02 (CI, 0 to 0.06) when both test results were negative.
Local standards for tuberculin skin testing differed from others used internationally. The study sample included few immunosuppressed patients.
The ELISpot(PLUS) assay is more sensitive than standard ELISpot and, when used in combination with tuberculin skin testing, enables rapid exclusion of active infection in patients with moderate to high pretest probability of tuberculosis.
新型基于T细胞的血液检测在活动性结核病诊断中的作用尚不清楚。
比较两种干扰素-γ检测方法和结核菌素皮肤试验在疑似结核病成人中的性能。
在常规实践中进行的前瞻性研究。
英国的两家城市医院。
389名成年人,主要为南亚和黑人种族,临床高度怀疑为活动性结核病。
在诊断评估期间,由对其他检测结果不知情的独立人员进行结核菌素皮肤试验、包含早期分泌性抗原靶标6和培养滤液蛋白10的酶联免疫斑点试验(标准ELISpot)以及包含新型抗原Rv3879c的ELISpot(ELISpot(PLUS))。
敏感性、特异性、预测值和似然比。
194例患者最终诊断为活动性结核病,其中79%经培养确诊。ELISpot(PLUS)对培养确诊和高度疑似结核病的敏感性为89%(95%CI,84%至93%),标准ELISpot为85%(CI,79%至90%),结核菌素皮肤试验15毫米阈值时为79%(CI,72%至85%),接种疫苗和未接种疫苗患者分别采用15毫米和10毫米分层阈值时为83%(CI,77%至89%)。ELISpot(PLUS)检测比15毫米截断点的结核菌素皮肤试验更敏感(P = 0.01),但分层截断点时则不然(P = 0.10)。ELISpot(PLUS)检测的诊断敏感性比标准ELISpot高4%(P = 0.02)。ELISpot(PLUS)和结核菌素皮肤试验的联合敏感性为99%(CI,95%至100%),当两种检测结果均为阴性时,阴性似然比为0.02(CI,0至0.06)。
结核菌素皮肤试验的当地标准与国际上使用的其他标准不同。研究样本中免疫抑制患者较少。
ELISpot(PLUS)检测比标准ELISpot更敏感,与结核菌素皮肤试验联合使用时,能够快速排除结核病预测试验概率为中度至高度的患者的活动性感染。